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tioning regimen has yet to be determined as data is limited.
Also, most of these studies have used a one-day washout
formelphalan prior to stem cell infusion.
Patients and Methods: We conducted a retrospective study
of 17 patients with multiple myeloma on hemodialysis who
underwent ASCT over a period of 8 years at a single institu-
tion. All patients underwent ASCT with the same condi-
tioning regimen that consisted of melphalan 70mg/m2 days
-4 and -3, for a total of melphalan 140mg/m2, followed by a
two-day washout period on days -2 and day -1 with stem cell
infusion on day 0. Patients underwent hemodialysis on day
-4 prior to the ﬁrst dose of melphalan, day -2 (24 hours after
2nd dose of melphalan is given), and again on day 0. A two-
day washout was used to allow a longer duration for
melphalan to clear prior to stem cell infusion. OS was
calculated from day of transplant to date of death or last
follow up.
Results: A total of 17 patients on hemodialysis with multiple
myeloma underwent ASCT between April 2006 and May
2014 with high-dose melphalan and two-day washout. The
median number of therapies prior to transplant was 1.5
(range, 1-3) with only 4 (24%) of patients VGPR at the time
of transplant. There were 6 (35%) patients with grade III
toxicity (majority were mucositis) and no grade IV toxicities
reported. The median time to engraftment was 11 days
(range, 10-16) and the best response post-ASCT by 1year
evaluation included the following: 11 (65%) patients with CR,
2 (7%) VGPR, 3 PR (18%), 1 (6%) patient with stable disease,
and 1 patient was inevaluable because of death before 1 year
post-ASCT response assessment. There were no deaths
within the 100 days of ASCT; however one patient died of
septic shock before 1 year post-ASCT response assessment.
At a median follow up of 2.7 years, the overall survival wasFigure 1. Overall survival.
Figure 2. Time to progression.w6.5 years (Figure 1) and time to progression w5 years
(Figure 2).
Conclusions: This is a single institution retrospective study
demonstrating that high-dose melphalan with a two-day
washout in patients with multiple myeloma on hemodialysis
is a safe regimenwith a lower toxicity, reducedmortality and
deep remissions. Future prospective studies are needed to
conﬁrm the reduced toxicity and continued beneﬁt of this
approach.139
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Background: High-dose chemotherapy and autologous pe-
ripheral blood stem cell (PBSC) transplantation is considered
a standard of care procedure for multiple hematological
malignances. Patients undergoing this procedure might face
multiple morbidities including mucosal inﬂammation and
neutropenic fever; both related to neutropenia. Based on our
pre-clinical work in an umbilical cord blood (UCB) trans-
plantation murine model, we found that hyperbaric oxygen
(HBO) improved UCB CD34+ cell engraftment. As a result, we
are currently conducting a pilot study exploring HBO in
clinical autologous PBSC transplantation. Our primary aim is
to determine the safety of HBO in this setting and secondarily
to determine its efﬁcacy in reducing time to neutrophil and
platelet engraftment compared to matched historic controls.
Materials/Methods: Patients with multiple myeloma (MM),
non-Hodgkin’s lymphoma (NHL) and Hodgkin’s disease (HD)
that require autologous PBSC transplantation were included.
On day 0, patients received HBO treatment consisting of
exposure to 2.5 atmosphere absolutes for a total of 2 hours, in
a monoplace hyperbaric chamber, breathing 100% oxygen.
Six hours from the start of HBO, PBSC units were infused and
patients were followed daily for toxicity and blood count
recovery. A matched historic cohort was chosen based on
gender, age, conditioning regimen, and disease type.
Results: 16 patients were screened for this study, 13 were
enrolled, and 11 were treated. One patient did not get treated
because of an emergency use of the HBO chamber by another
patient. The main reasons for non-enrollment were insur-
ance denial, patient choice, and failure to meet study criteria.
The treated subjects were 6 males and 5 females with me-
dian age of 63 (range: 25-67) who had MM (n¼7), or NHL
(n¼4). For MM patients, the preparative regimen was high-
dose melphalan and for NHL patients it was BEAM or BEAC.
The median cell dose infused was 3.7 (2.52-6.11) X106 CD34/
Kg recipient body weight. Only one patient was unable to
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completed therapy without subsequent treatment limiting
toxicity. For the eleven patients who were assessed for
engraftment, the median time to neutrophil count recovery
was day 11 (10-13) and for platelet count recovery was day
16 (14-19) post-transplant. In this unplanned interim anal-
ysis, the historical control group was estimated to have a
longer average time to neutrophil recovery (0.15 days with a
standard error of 0.32) and a longer average log-transformed
time to platelet recovery (approximately 0.16 log-days with a
standard error of 0.08), which transformed into days repre-
sents about 1.2 days.
Conclusion: HBO therapy prior to PBSC cell infusion appears
to be well tolerated in the setting of high-dose therapy and
autologous PBSC transplantation. HBO impact on blood count
recovery should be investigated further.
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Introduction: Poor peripheral blood stem cell (PBSC)
mobilization has been shown to be associated with worse
outcomes in lymphoma patients undergoing autologous
stem cell transplantation (ASCT). The impact of poor mobi-
lization on the outcome of ASCT in multiple myeloma (MM)
patients has not been well studied. In this single institution
retrospective study, we evaluated the effect of poor mobili-
zation on PFS and OS for MM patients undergoing ASCT.
Methods:We collected data retrospectively for patients with
MMwho underwent ASCT between Jan. 2001 and Dec. 2010.
Patients were initially mobilized with standard-dose (10
mcg/kg/day) granulocyte colony stimulating factor. Patients
were classiﬁed as poor mobilizers if they failed to collect >
4106 CD34+ cells/kg from all apheresis attempts. The log-
rank test was used to analyze PFS (from ASCT to ﬁrst relapse)
and OS (from diagnosis to death) for both groups. Multivar-
iate analysis by the Cox proportional hazards model was
used to assess the correlation of mobilization with other
known prognostic variables and PFS and OS.
Results: Total of 271 patients were identiﬁed for study in-
clusion. Of these, 13 patients were excluded due to loss of
follow-up beyond 6 months (8), progressive disease through
ASCT (3), development of secondmalignancies (2). The mean
length of follow-up for all patients was 74.5 months. Thirty-
seven (14.3%) patients were poor mobilizers and 221 (85.7%)
were good mobilizers. Univariate analysis showed no sig-
niﬁcant difference between the two groups in regards to age,
gender, beta-2 microglobulin (B2M) level at diagnosis, and
disease status at time of ASCT, but there was signiﬁcant dif-
ferences in disease stage at presentation (86.5% had Durie-
Salmon disease stage 3A or 3B vs. 63.8%, p ¼ 0.007), numberof prior chemotherapy regimens (67.6% had  2 prior regi-
mens vs. 43.8%, p ¼ 0.005), and ideal body weight (median
67.2 vs. 62.3 kg, p ¼ 0.015) in poor vs. good mobilizers,
respectively. Survival analysis for poor versus good mobi-
lizers showed a median PFS of 24.7 months vs. 28.7 months
(p¼ 0.08) and median OS of 52.8 months vs. 106.8 months (p
< 0.0001), respectively. Cox PH regression multivariate
analysis showed signiﬁcant correlation of PFS to disease
stage and number of prior chemotherapy regimens, while
B2M and number of prior chemotherapy regimens correlated
signiﬁcantly to OS. However, poor mobilization was not
signiﬁcantly correlated to PFS (p ¼ 0.963) or OS (p ¼ 0.087).
After ASCT, good mobilizers were more likely to be in VGPR/
CR than poor mobilizers (53.4 vs. 37.8%, respectively).
Conclusions: Poor PBSC mobilization is associated with
worse long-term outcomes inMMpatients undergoing ASCT.
Our data suggests that poor mobilization was not an inde-
pendent predictive factor, possibly due to small number of
patients, but signiﬁcantly associated with a more advanced
disease stage and  2 of pre-transplant chemotherapy regi-
mens.
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Background: Evidence based dosing of high-dose Cyclo-
phosphamide (Cy) in obese patients remains elusive and
some studies have identiﬁed obesity a risk factor for non-
relapse mortality (NRM). We studied an adjusted body
weight (ABW50) Cy dosing method in morbidly obese pa-
tients (body mass index >30) undergoing high dose Cy
conditioning and autologous HCT.
Patients & Methods: We analyzed 147 patients with non-
Hodgkin lymphoma (NHL) who received Cy (120 mg/kg IV) +
fractionated total body irradiation (TBI; 1320 cGy) condi-
tioning (2001e2012) in 3 groups divided by bodyweight: not
obese (<120% ideal body weight (IBW); n¼72), obese (120-
149% IBW; n¼46) and morbidly obese (150% IBW; n¼29).
Patients <150% of IBW were dosed using actual body weight
(ABW). In morbidly obese patients, total Cy was calculated
using adjusted body weight (ABW50) formula: IBW +
0.5(ABWeIBW). Patients had NHL (diffuse large B cell lym-
phoma n¼57, mantle cell lymphoma n¼51 and others n¼39)
with median age 57 years (range 19-73) and median follow
up 2 years (range 1-9 yrs).
Results: NRM at 1 year was 4% and not different in 3 weight
groups. Overall survival (OS) at 4 years for non-obese was
54% (95% CI 40-67), obese 64% (95% CI 44-79), morbidly
obese 64% (95% CI 37-82). Cumulative incidence of relapse
was similar in 3 groups: 46% (95% CI: 36-55%); 44% (95%
CI:28-60%) vs 48% (95% CI: 26-70%). Multivariable regression
showed similar OS and relapse when adjusted for gender and
disease status (Table). No differences were seen among
weight groups regarding incidence of neutrophil and
platelet engraftment, hemorrhagic cystitis or cardiac
toxicity (congestive heart failure).
Conclusion: We report the ﬁrst prospective testing of efﬁ-
cacy and safety of weight-adjusted correction of Cy dosing
